Aflunov^®: a prepandemic influenza vaccine

References

• Ghedin E, Sengamalay NA, Shumway M et al. Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution. Nature 20, 437(7062), 1162–1166 (2005).
   PubMed Web of Science ®Google Scholar
• The Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med.360, 2605–2615 (2009).
   PubMed Web of Science ®Google Scholar
• Tognotti E. Influenza pandemics: a historical retrospect. J. Infect. Dev. Ctries3(5), 331–334 (2009).
   PubMed Web of Science ®Google Scholar
• Yildizdas D, Kendirli T, Arslanköylü AE et al. Neurological complications of pandemic influenza (H1N1) in children. Eur. J. Pediatr.170(6), 779–788 (2011).
   PubMed Web of Science ®Google Scholar
• Brammer L, Blanton L, Epperson S et al. Surveillance for influenza during the 2009 influenza A (H1N1) pandemic – United States, April 2009–March 2010. Clin. Infect. Dis.52(Suppl. 1), S27–S35 (2011).
   PubMed Web of Science ®Google Scholar
• Cox CM, Blanton L, Dhara R, Brammer L, Finelli L. 2009 pandemic influenza A (H1N1) deaths among children-United States, 2009–2010. Clin. Infect. Dis.52(Suppl. 1), S69–S74 (2011).
   PubMed Web of Science ®Google Scholar
• Marks G, Beatty WK. Epidemics. Scribner, NY, USA (1976).
   Google Scholar
• Hirsch A. Handbuch der historisch geographischen pathologie. Ferdinand Enke, Stoccarda, Germany (1883–1886).
   Google Scholar
• Miller MA, Viboud C, Balinska M, Simonsen L. The signature features of influenza pandemics – implications for policy. N. Engl. J. Med.360, 2595–2598 (2009).
   PubMed Web of Science ®Google Scholar
• Taubenberger JK, Morens DM. 1918 influenza: the mother of all pandemics. Emerg. Infect. Dis.12, 15–22 (2006).
   PubMed Web of Science ®Google Scholar
• Oakes JO. Epidemic influenza: a survey. American Medical Association, IL, USA (1927).
   Google Scholar
• Osterholm MT. Preparing for the next pandemic. N. Engl. J. Med.352, 1839–1842 (2005).
   PubMed Web of Science ®Google Scholar
• Taubenberger JK. The virulence of the 1918 pandemic influenza virus: unraveling the enigma. Arch. Virol. Suppl.19, 101–115 (2005).
   Google Scholar
• Hulse DJ, Webster RG, Russell RJ, Perez DR. Molecular determinants within the surface proteins involved in the pathogenicity of H5N1 influenza viruses in chickens. J. Virol.78, 9954–9964 (2004).
   PubMed Web of Science ®Google Scholar
• Petterson KD, Pyele GF. The geography and mortality of the 1918 influenza pandemic. Bull. Hist. Med.65, 4–21 (1991).
   PubMed Web of Science ®Google Scholar
• Kilbourne ED. Influenza pandemics of the 20th century. Emerg. Infect. Dis.12, 9–14 (2006).
   PubMed Web of Science ®Google Scholar
• Sencer DJ, Millar JD. Reflections on the 1976 swine flu vaccination program. Emerg. Infect. Dis.12(1), 29–33 (2006).
   PubMed Web of Science ®Google Scholar
• Easterday BC. The enigma of zoonotic influenza. In: Proceedings of the 3rd Symposium on Microbiology. World Health Organisation Collaborating Centre for Collation and Evaluation of Data on Comparative Virology, Munich, Germany, 102–107 (1978).
   Google Scholar
• Dasco CC, Couch RB, Six HR, Young WF, Quarles JM, Kasel JA. Sporadic occurrence of zoonotic swine influenza virus infections. J. Clin. Microbiol.20, 833–835 (1984).
   PubMed Web of Science ®Google Scholar
• Rota PA, Rocha EP, Harmon MW et al. Laboratory characterization of a swine influenza virus isolated from a fatal case of human influenza. J. Clin. Microbiol.27, 1413–1416 (1989).
   PubMed Web of Science ®Google Scholar
• Thompson BL, Xu X, Regnery HL et al. An influenza A (H1N1) virus, closely related to swine influenza virus, responsible for a fatal case of human influenza. J. Virol.68, 2051–2058 (1994).
   PubMed Web of Science ®Google Scholar
• Brown IH. The epidemiology and evolution of influenza viruses in pigs. Vet. Microbiol.74, 29–46 (2000).
   PubMed Web of Science ®Google Scholar
• Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G, Fanning TG. Characterization of the 1918 influenza virus polymerase genes. Nature437, 889–893 (2005).
   PubMed Web of Science ®Google Scholar
• Kurtz J, Manvell RJ, Banks J. Avian influenza virus isolated from a woman with conjunctivitis. Lancet348, 901–902 (1996).
   PubMed Web of Science ®Google Scholar
• Webby RJ, Webster G. Are we ready for pandemic influenza? Science302, 1519–1522 (2003).
   PubMed Web of Science ®Google Scholar
• Fouchier RA, Schneeberger PM, Rozendaal FW et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc. Natl Acad. Sci. USA101(5), 1356–1361 (2004).
   PubMed Web of Science ®Google Scholar
• Thiry E, Zicola A, Addie D et al. Highly pathogenic avian influenza H5N1 virus in cats and other carnivores. Vet. Microbiol.122(1–2), 25–31 (2007).
   PubMed Web of Science ®Google Scholar
• Keawcharoen J, Oraveerakul K, Kuiken T et al. Avian influenza H5N1 in tigers and leopards. Emerg. Infect. Dis.10(12), 2189–2191 (2004).
   PubMed Web of Science ®Google Scholar
• Babakir-Mina M, Ciccozzi M, Ciotti M et al. Phylogenetic analysis of the surface proteins of influenza A (H5N1) viruses isolated in Asian and African populations. N. Microbiol.32, 397–403 (2009).
   PubMed Web of Science ®Google Scholar
• Duan L, Fan XH, Leung YH et al. Characterization of low-pathogenic H5 subtype influenza viruses from Eurasia: implications for the origin of highly pathogenic H5N1 viruses. J. Virol.81, 7529–7539 (2007).
   PubMed Web of Science ®Google Scholar
• Ducatez MF, Olinger CM, Owoade AA et al. Molecular and antigenic evolution and geographical spread of H5N1 highly pathogenic avian influenza viruses in western Africa. J. Gen. Virol.88, 2297–2306 (2007).
   PubMed Web of Science ®Google Scholar
• Chen H, Smith GJD, Li KS et al. Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc. Natl Acad. Sci. USA103, 2845–2850 (2006).
   PubMed Web of Science ®Google Scholar
• Salzberg SL, Kingsford C, Cattoli G et al. Genome analysis linking recent European and African influenza (H5N1) viruses. Emerg. Infect. Dis.13, 713–718 (2007).
   PubMed Web of Science ®Google Scholar
• Smith GJD, Fan XH, Wang J et al. Emergence and predominance of an H5N1 influenza variant in China. Proc. Natl Acad. Sci. USA103, 16936–16941 (2006).
   PubMed Web of Science ®Google Scholar
• Smith GJD, Naipospos TSP, Nguyen TD et al. Evolution and adaptation of H5N1 influenza virus in avian and human hosts in Indonesia and Vietnam. Virology350, 258–268 (2006).
   PubMed Web of Science ®Google Scholar
• Wallace RG, Hodac H, Lathrop RH, Fitch WM. A statistical phylogeography of influenza A H5N1. Proc. Natl Acad. Sci. USA104, 4473–4478 (2007).
   PubMed Web of Science ®Google Scholar
• Duan L, Campitelli L, Fan XH et al. Characterization of low-pathogenic H5 subtype influenza viruses from Eurasia: implications for the origin of highly pathogenic H5N1 viruses. J. Virol.81, 7529–7539 (2007).
   PubMed Web of Science ®Google Scholar
• Osterhaus A. Pre- or post-pandemic influenza vaccine? Vaccine25, 4983–4984 (2007).
   PubMed Web of Science ®Google Scholar
• Gambotto A, Barratt-Boyes SM, de Jong MD, Neumann G, Kawaoka Y. Human infection with highly pathogenic H5N1 influenza virus. Lancet371, 1464–1475 (2008)
   PubMed Web of Science ®Google Scholar
• Dupuis M, Murphy TJ, Higgins D et al. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol.186, 18–27 (1998).
   PubMed Web of Science ®Google Scholar
• Schultze V, D’Agosto V, Wack A et al. Safety of MF59 adjuvant. Vaccine26, 3209–3222 (2008).
   PubMed Web of Science ®Google Scholar
• Durando P, Fenoglio D, Boschini A et al. Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus Type 1-seropositive and -seronegative adults. Clin. Vaccin. Immunol.15, 253–259 (2008).
   PubMed Web of Science ®Google Scholar
• Banzhoff A, Gasparini R, Laghi-Pasini F et al. MF59H-Adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE4(2), e4384 (2009).
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Van der Wielen M, Kafeja F et al. Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults. Vaccine27, 6918–6925 (2009).
   PubMed Web of Science ®Google Scholar
• Denis M. Update on H5N1 vaccines Sanofi Pasteur. Presented at: 5th WHO Meeting on evaluation of pandemic influenza prototype vaccines in clinical trials. Geneva, Switzerland, 12–13 February 2009.
   Google Scholar
• Wu J, Liu SZ, Dong SS et al. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a Phase 1–2 randomized trial. Vaccine28, 6221–6227 (2010).
   PubMed Web of Science ®Google Scholar
• Nolan T, Richmond PC, Formica NT et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine26, 6383–6391 (2008).
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Colegate AC, Podda A et al. Safety and antigenicity of nonadjuvanted and MF59-adjuvanted influenza A/duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet357, 1937–1943 (2001).
   PubMed Web of Science ®Google Scholar
• Stephenson I, Nicholson KG, Colegate A et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/duck/Singapore/97 vaccine in a primed human population. Vaccine21, 1687–1693 (2003).
   PubMed Web of Science ®Google Scholar
• Fragapane E, Gasparini R, Schioppa F, Laghi-Pasini F, Montomoli E, Banzhoff A. A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. Clin. Vaccin. Immunol.17, 1817–1819 (2010).
   PubMedGoogle Scholar
• Stephenson I, Bugarini R, Nicholson KG et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis.191, 1210–1215 (2005).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Tilman S et al. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics126(4), 762–770 (2010).
   PubMed Web of Science ®Google Scholar
• Rowe T, Abernathy RA, Hu-Primmer J et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serological assays. J. Clin. Microbiol.37, 937–943 (1999).
   PubMed Web of Science ®Google Scholar
• Oxford JS, Yetts R, Schild GC. Quantitation and analysis of the specificity of post-immunization antibodies to influenza B viruses using single radial haemolysis. J. Hyg. (Lond.).88, 325–333 (1982).
   PubMedGoogle Scholar
• Lin JT, Li CG, Wang X et al. Antibody persistence after 2-dose priming and booster response to a third dose of an inactivated, adjuvanted, whole-virion H5N1 vaccine. J. Infect. Dis.199, 184–187 (2009).
   PubMed Web of Science ®Google Scholar
• Nolan T, Richmond PC, Skeljo MV et al. Phase 1 and 2 randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine26, 4160–4167 (2008).
   PubMed Web of Science ®Google Scholar
• Stephenson I, Nicholson KG, Hoschler K et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N. Engl. J. Med.359, 1631–1633 (2008).
   PubMed Web of Science ®Google Scholar
• Galli G, Medini D, Borgogni E et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl Acad. Sci. USA106, 3877–3882 (2009).
   PubMed Web of Science ®Google Scholar
• Sasaki S, Jaimes MC, Holmes TH et al. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J. Virol.81, 215–228 (2007).
   PubMed Web of Science ®Google Scholar
• Wrammert J, Smith K, Miller J et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature453, 667–671 (2008).
   PubMed Web of Science ®Google Scholar
• Avian influenza A (H5N1) infection in humans. The writing committee of the World Health Organization (WHO) consultation on human influenza A/H5. N. Engl. J. Med.353, 1374–1385 (2005).
   PubMed Web of Science ®Google Scholar